Literature DB >> 27822751

Memantine attenuates cognitive impairments after status epilepticus induced in a lithium-pilocarpine model.

S V Kalemenev1, O E Zubareva1,2, V V Sizov2, V V Lavrent'eva1, N Ya Lukomskaya1, K Kh Kim1, A V Zaitsev1, L G Magazanik3,4.   

Abstract

The capability of memantine, a noncompetitive antagonist of the NMDA receptors, to prevent impairments of cognitive functions in rats was investigated in the lithium-pilocarpine model of epilepsy. After status epilepticus, rats exhibited impaired exploratory behavior and spatial memory, and a decline of extinction of orienting behavior. Memantine administration prevented these disturbances. Thus, the blockade of the NMDA receptors immediately after status epilepticus allowed prevention of the development of the possible cognitive impairments.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27822751     DOI： 10.1134/S0012496616050148

Source DB:  PubMed          Journal:  Dokl Biol Sci        ISSN： 0012-4966


  15 in total

Review 1.  Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.

Authors:  Stuart A Lipton
Journal:  NeuroRx       Date:  2004-01

2.  A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice.

Authors:  T Kos; P Popik
Journal:  Behav Pharmacol       Date:  2005-05       Impact factor: 2.293

3.  [The influence of neonatal interleukin-1beta increase on the formation of adult rats' spatial memory].

Authors:  A N Trofimov; O E Zubareva; A S Simbirtsev; V M Klimenko
Journal:  Ross Fiziol Zh Im I M Sechenova       Date:  2012-06

Review 4.  Psychiatric comorbidity in epilepsy.

Authors:  W A M Swinkels; J Kuyk; R van Dyck; Ph Spinhoven
Journal:  Epilepsy Behav       Date:  2005-08       Impact factor: 2.937

5.  N-methyl-D-aspartate receptor channel blockers prevent pentylenetetrazole-induced convulsions and morphological changes in rat brain neurons.

Authors:  Aleksey V Zaitsev; Kira Kh Kim; Dmitry S Vasilev; Nera Ya Lukomskaya; Valeria V Lavrentyeva; Natalia L Tumanova; Igor A Zhuravin; Lev G Magazanik
Journal:  J Neurosci Res       Date:  2014-10-31       Impact factor: 4.164

6.  Status epilepticus causes long-term NMDA receptor-dependent behavioral changes and cognitive deficits.

Authors:  A C Rice; C L Floyd; B G Lyeth; R J Hamm; R J DeLorenzo
Journal:  Epilepsia       Date:  1998-11       Impact factor: 5.864

7.  Impairment of exploratory behavior and spatial memory in adolescent rats in lithium-pilocarpine model of temporal lobe epilepsy.

Authors:  S V Kalemenev; O E Zubareva; E V Frolova; V V Sizov; V V Lavrentyeva; N Ya Lukomskaya; K Kh Kim; A V Zaitsev; L G Magazanik
Journal:  Dokl Biol Sci       Date:  2015-09-03

Review 8.  Research advances in basic mechanisms of seizures and antiepileptic drug action.

Authors:  Władysław Lasoń; Małgorzata Chlebicka; Konrad Rejdak
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

9.  Long-term NMDAR antagonism correlates reduced astrocytic glutamate uptake with anxiety-like phenotype.

Authors:  Eduardo R Zimmer; Vitor R Torrez; Eduardo Kalinine; Marina C Augustin; Kamila C Zenki; Roberto F Almeida; Gisele Hansel; Alexandre P Muller; Diogo O Souza; Rodrigo Machado-Vieira; Luis V Portela
Journal:  Front Cell Neurosci       Date:  2015-06-03       Impact factor: 5.505

Review 10.  Pathophysiogenesis of mesial temporal lobe epilepsy: is prevention of damage antiepileptogenic?

Authors:  G Curia; C Lucchi; J Vinet; F Gualtieri; C Marinelli; A Torsello; L Costantino; G Biagini
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530
View more
  1 in total

1.  Validating a model of benzodiazepine refractory nerve agent-induced status epilepticus by evaluating the anticonvulsant and neuroprotective effects of scopolamine, memantine, and phenobarbital.

Authors:  Cecelia Jackson; Cherish Ardinger; Kristin M Winter; John H McDonough; Hilary S McCarren
Journal:  J Pharmacol Toxicol Methods       Date:  2019-02-19       Impact factor: 2.285
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.